跳至主要内容
临床试验/CTRI/2025/07/090258
CTRI/2025/07/090258尚未招募不适用

Prophylactic effects of the homoeopathic medicine Eupatorium perfoliatum 30CH during the dengue outbreak in Kolkata: A comparative cohort study

Department of Science and Technology, Govt of West Bengal1 个研究点 分布在 1 个国家目标入组 1,614 人开始时间: 2025年9月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,614
试验地点
1
主要终点
Group differences in the occurrence of confirmed dengue fever

研究概览

简要总结

Dengue is a major public health concern globally and a common cause of illness seen in primary care settings in tropical and subtropical countries. It is endemic in more than 100 countries in Africa, America, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. This research on 1614 participants is aimed at contributing to the growing evidence base of prophylactic effects of the homeopathic medicine Eupatorium perfoliatum (EP) 30CH against dengue in Kolkata using a parallel cohort design. The primary objective of the study is to detect the group differences in the occurrence of confirmed dengue fever (DF) cases, while the secondary objective is to detect the group differences in the occurrence of probable DF cases and hospitalization. The homeopathic medication Eupatorium perfoliatum 30CH can be a promising preventive option for dengue, as evidenced by several preclinical and clinical findings. Effective dengue vaccines are yet to be developed and approved. In the meantime, this research may help reduce the occurrence of DF cases, thereby reducing the financial burden of the community. This work will add to the growing evidence base of the homeopathic medicine EP 30CH as a potent prophylactic for DF.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
1.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • a) Healthy individuals of either sex or transgender b) Aged 1 year or above c) Providing with written informed assent and/or consent voluntarily.

排除标准

  • a) Persons having symptoms of dengue-like illness or fever in the last 7 days b) Individuals taking other preventive medicines for dengue c) Individuals with self-reported immunocompromised states d) Malignancies and other life-threatening or end-stage diseases e) Pregnant, puerperal, and lactating women f) Substance abuse and/or dependence g) Simultaneous participation in any clinical trial.

结局指标

主要结局

Group differences in the occurrence of confirmed dengue fever

时间窗: Baseline and 5 months of the current year; to be repeated again for next two years

(DF) cases.

时间窗: Baseline and 5 months of the current year; to be repeated again for next two years

次要结局

  • Group differences in the occurrence of probable dengue fever cases & hospitalization(Baseline & 5 months of the current year; to be repeated again for next two years)

研究者

发起方
Department of Science and Technology, Govt of West Bengal
申办方类型
Government funding agency
责任方
Principal Investigator
主要研究者

Sangita Saha

D. N. De Homoeopathic Medical College and Hospital

研究点 (1)

Loading locations...

相似试验